• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

    6/17/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email

    --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio--

    ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on expanding the U.S. infertility market and building key international partners.

    "We are pleased to welcome Kelley Nicholas to Femasys during this important early phase of commercial growth," said Kathy Lee-Sepsick, CEO and Founder of Femasys. "Kelley brings a proven track record of driving substantial revenue growth and creating shareholder value, aligning with our strategic priorities. Her results-driven leadership and executional focus will be key as we expand access to our fertility solutions in the U.S. and build impactful global partnerships across our broader product portfolio."

    "I am honored to join Femasys at such a pivotal time in its growth trajectory," said Kelley Nicholas, CCO of Femasys. "With a background in driving commercial execution and scaling revenue across healthcare markets, I am confident I can meaningfully contribute to accelerating growth and strengthening Femasys' position in women's health."

    Ms. Nicholas has over 25 years of industry experience, including two decades leading high-performing commercial teams. She has a strong record of driving revenue growth, expanding markets, and leading transformative strategies in the medical device and biotechnology sectors. Prior to joining Femasys, Ms. Nicholas served as Head of Sales at NeuroPace, where she spearheaded a commercial overhaul that dramatically accelerated revenue, profitability, and stock performance. In her role as Global Vice President of Marketing at Hologic, she restructured the commercial organization and revamped product development, launch effectiveness, and global commercialization which led to top line revenue growth across all business units. Kelley's leadership experience spans global healthcare companies like Medtronic, Baxter, Intuitive Surgical and Covidien where she led multiple go-to-market strategy transformations and organizational scale-ups which contributed to the successful commercialization of disruptive technologies. She is known for building energized, accountable teams, and aligning strategic vision with execution to deliver sustainable growth. Ms. Nicholas holds a BS in Health Science and Physical Therapy from the University of Missouri and a master's in business administration from Washington University.

    Grant of Inducement Option

    In connection with the appointment of Ms. Nicholas, Femasys has granted to Ms. Nicholas, to be effective as of her first day of employment, an option to purchase 100,000 shares of Femasys common stock at an exercise price per share equal to the closing price of Femasys common stock on the grant date as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys' Board of Directors and made as an inducement material to Ms. Nicholas entering into employment with Femasys as contemplated by Nasdaq Listing Rule 5635(c)(4).

    The stock option will vest as to 25% of the shares underlying the stock option on the first anniversary of the commencement of employment, with the remaining shares vesting 25% each year over the following three years, subject to Ms. Nicholas's continued employment with Femasys. Femasys provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Femasys

    Femasys is a leading biomedical innovator focused on addressing critical unmet needs in women's health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys' fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data show FemaSeed is over twice as effective as traditional IUI, for low male sperm count, with a comparable safety profile, and high patient and practitioner satisfaction.1

    FemBloc® permanent birth control, the first and only non-surgical, in-office alternative to centuries-old surgical sterilization, expects full regulatory approval in Europe mid-year 2025. Commercialization of this highly cost effective, convenient and significantly safer approach, will begin in Spain through engaged partnerships followed by select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is ongoing. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

    References

    1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

    2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

    Forward-Looking Statements 

    This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "pending," "intend," "believe," "suggests," "potential," "hope," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: market and other conditions; our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof and ability to raise sufficient capital for such model and plans; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

    Contacts: 

    Investors: 

    [email protected]

    Media Contact: 

    [email protected]



    Primary Logo

    Get the next $FEMY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

      ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

      3/21/24 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

      -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

      2/6/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JonesTrading initiated coverage on Femasys with a new price target

      JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

      7/13/21 11:41:28 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chardan Capital initiated coverage on Femasys with a new price target

      Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

      7/13/21 8:04:59 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    SEC Filings

    See more
    • Femasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:22:54 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by Femasys Inc.

      S-3 - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:19:58 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/1/25 9:20:38 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

      -- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. "Securing regulatory approvals in Australia and New Zealand mark another important step in expand

      7/1/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

      ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc® System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification. The regulatory approval for the blended

      6/25/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Nicholas Kelley Stinson

      4 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:57:48 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • New insider Nicholas Kelley Stinson claimed ownership of 125 shares (SEC Form 3)

      3 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:54:34 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Silverman Joshua

      4 - FEMASYS INC (0001339005) (Issuer)

      6/27/25 5:25:24 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Financials

    Live finance-specific insights

    See more
    • Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

      -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

      5/8/25 5:01:00 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

      -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

      3/27/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

      ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

      11/12/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Femasys Inc.

      SC 13D - FEMASYS INC (0001339005) (Subject)

      11/22/23 4:00:15 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care